Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Dyclonine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.95 |
| ▸ | LMNA | P02545 | 7/20 | 0.95 |
| ▸ | HRH2 | P25021 | 4/20 | 0.95 |
| ▸ | HRH1 | P35367 | 4/20 | 0.95 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | DRD4 | P21917 | 1/20 | 0.95 |
| ▸ | ACHE | P22303 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.95 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dyclonine SCHEMBL25773 | 0.97 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| SCHEMBL29766083 | 0.97 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| Dyclonine SCHEMBL317219 | 0.96 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| Propipocaine SCHEMBL1650998 | 0.95 | ALDH1A1 (0.93) | THRBALDH1A1LMNAHRH2HRH1 | |
| SCHEMBL11231907 | 0.94 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| SCHEMBL9320014 | 0.94 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| SCHEMBL9320006 | 0.94 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| SCHEMBL9319585 | 0.94 | THRB (1.00) | THRBALDH1A1LMNAHRH2HRH1 | |
| Dyclonine SCHEMBL8662373 | 0.93 | THRB (0.90) | THRBALDH1A1LMNAHRH2HRH1 | |
| Hydrochloric Acid SCHEMBL11234596 | 0.93 | THRB (0.98) | THRBALDH1A1LMNAHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250195523-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2025-06-19 | — | — | US | disclosed |
| EP-4496574-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2025-01-29 | — | — | EP | disclosed |
| CN-119350149-A | 1- (4-Butoxyphenyl) -3-hydroxypropyl-1-one and preparation method and application thereof | 北京茗泽中和药物研究有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350150-A | 4-Butoxyphenyl propenone and preparation method and application thereof | 北京茗泽中和药物研究有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023180474-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2023-09-28 | — | — | WO | disclosed |
| CN-114767624-A | Pharmaceutical composition containing 4-butoxy-beta-piperidyl propiophenone compound and preparation method and application thereof | 南京唯创远医药科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1951262-A2 | METHODS OF USING SMALL MOLECULE COMPOUNDS FOR NEUROPROTECTION | The Board of Trustees of the University of Alabama (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070203079-A1 | Methods of using small molecule compounds for neuroprotection | ALABAMA, UNIVERSITY OF | 2007-08-30 | — | — | US | disclosed |
| WO-2007062186-A2 | METHODS OF USING SMALL MOLECULE COMPOUNDS FOR NEUROPROTECTION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA FOR AND ON BEHALF OF THE UNIVERSITY OF ALABAMA (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195523-A1 | ORGANIC MOLECULES FOR TREATING MYELIN PATHOLOGIES | PMP22, MAG, MYT1 | THRB 4058/4885ALDH1A1 3506/4885LMNA 539/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | THRB 3769/4885ALDH1A1 568/4885LMNA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.